BACKGROUND: The screening of @entity3124 @entity1 at high risk of @entity2176 resistant enterococci (VRE) colonization, to detect and isolate colonized @entity1 , is recommended to prevent and control the transmission of VRE. Screening asymptomatic carriers brings financial burden for institutions. In this study, we performed risk analysis for VRE colonization and determined the financial burden of screening in a middle-income country, @entity233 . METHODS: We retrospectively analyzed the VRE surveillance data from a pediatric hospital between 2010 and 2014. A case-control study was conducted to identify the risk factors of colonization. Total cost of VRE screening and additional costs for a VRE colonized @entity1 (including active surveillance cultures and contact isolation) were calculated. RESULTS: During the 4-year period, 6,372 @entity1 were screened for perirectal VRE colonization. The rate of culture-positive specimens among all @entity1 screened was 239 (3.75%). The rate of @entity281 was 0.04% (n = 3) among all @entity1 screened. Length of hospital stay, @entity5 , and being transferred from another institution were independently associated risk factors for colonization. Annual estimated costs for the laboratory were projected as  19,074 (76,295/4) for all @entity1 screened. Cost of contact isolation for each @entity1 colonized in a ward and an intensive care unit was  270 and  718, respectively. CONCLUSIONS: In developing countries, institutions should identify their own high-risk @entity1 ; screening priorities should be based on prevalence of @entity281 and hospital financial resources.

Is it worth screening for XXXX -resistant Enterococcus faecium colonization?: Financial burden of screening in a developing country.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity2176 :: ('MESH:D014640', 'Chemical') :: ['vancomycin'] @entity233 :: ('9103', 'Species') :: ['Turkey'] @entity5 :: ('MESH:D009369', 'Disease') :: ['malignancy'] @entity3124 :: ('MESH:D016638', 'Disease') :: ['critically ill'] @entity281 :: ('MESH:D007239', 'Disease') :: ['infection', 'VRE infection']
@entity2176 :: (MESH:D014640,Chemical) :: ['vancomycin']
